Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Under Secretary for Health Dr. Shereef Elnahal said Monday the VA needs extra funding to cover the costs of drugs such as ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

A new study suggests that 40% of American adults have conditions that could benefit from semaglutide treatment.

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The Biden administration has proposed a new plan to expand coverage of glucagon-like peptide-1 (GLP-1) medications such as ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

GLP-1 (glucagon-like peptide-1) medications reduce appetite by sending signals of fullness to the brain and slowing down ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

Those on the medications, known as GLP-1s or glucagon-like peptide-1, will additionally weigh in four times a month on "smart ...